Neuphoria Therapeutics Inc. has announced an amendment to its existing Rights Agreement, extending the expiration date of the related rights. The company filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission on October 23, 2026.
The amendment, designated as Amendment No. 1, was entered into by the Board of Directors of Neuphoria Therapeutics Inc. on October 23, 2026. The agreement was originally executed on October 27, 2025, between the company and Computershare Trust Company, N.A., acting as the Rights Agent.
Under the terms of the Amendment, the Final Expiration Date of the Original Rights Agreement has been extended. The new expiration date is set for the close of business on October 27, 2027. The extension remains valid unless the agreement is modified or terminated earlier.
The filing indicates that the rights are governed by the provisions of the Original Rights Agreement, subject to the modifications made by the Amendment. The full text of the Original Rights Agreement and the Amendment is attached as Exhibits 4.1 and 4.2, respectively, to the Form 8-K.
